Terms: = Skin cancer AND FAS, FAS1, 355, ENSG00000026103, FASTM, APO-1, P25445, CD95, ALPS1A, TNFRSF6, APT1 AND Prognosis
31 results:
1. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.
Wei X; Zou Z; Zhang W; Fang M; Zhang X; Luo Z; Chen J; Huang G; Zhang P; Cheng Y; Liu J; Liu J; Zhang J; Wu D; Chen Y; Ma X; Pan H; Jiang R; Liu X; Ren X; Tian H; Jia Z; Guo J; Si L
Eur J Cancer; 2024 May; 202():114008. PubMed ID: 38479118
[TBL] [Abstract] [Full Text] [Related]
2. PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity.
Gu Y; Lin X; Dong Y; Wood G; Seidah NG; Werstuck G; Major P; Bonert M; Kapoor A; Tang D
J Exp Clin Cancer Res; 2023 Jan; 42(1):2. PubMed ID: 36588164
[TBL] [Abstract] [Full Text] [Related]
3. Characteristics and outcomes of 727 patients with mycosis fungoides and Sézary syndrome from a Brazilian cohort.
Miyashiro D; Sanches JA
Int J Dermatol; 2022 Apr; 61(4):442-454. PubMed ID: 34435672
[TBL] [Abstract] [Full Text] [Related]
4. Obesity is not associated with disease-free interval, melanoma-specific survival, or overall survival in patients with clinical stage IB-II melanoma after SLNB.
Deckers EA; Kruijff S; Bastiaannet E; van Ginkel RJ; Hoekstra-Weebers JEHM; Hoekstra HJ
J Surg Oncol; 2021 Sep; 124(4):655-664. PubMed ID: 34085291
[TBL] [Abstract] [Full Text] [Related]
5. Estimating Cured Fractions of Uveal Melanoma.
Singh AD; Zabor EC; Radivoyevitch T
JAMA Ophthalmol; 2021 Feb; 139(2):174-181. PubMed ID: 33355644
[TBL] [Abstract] [Full Text] [Related]
6. Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy.
Tio M; Wang X; Carlino MS; Shivalingam B; Fogarty GB; Guminski AD; Lo S; Hong AM; Menzies AM; Long GV
Pigment Cell Melanoma Res; 2018 Jul; 31(4):509-515. PubMed ID: 29277979
[TBL] [Abstract] [Full Text] [Related]
7. PRL-3/PTP4A3 phosphatase regulates integrin β1 in adhesion structures during migration of human ocular melanoma cells.
Foy M; Anézo O; Saule S; Planque N
Exp Cell Res; 2017 Apr; 353(2):88-99. PubMed ID: 28284838
[TBL] [Abstract] [Full Text] [Related]
8. The overriding of TRAIL resistance by the histone deacetylase inhibitor MS-275 involves c-myc up-regulation in cutaneous, uveal, and mucosal melanoma.
Venza M; Visalli M; Oteri R; Agliano F; Morabito S; Teti D; Venza I
Int Immunopharmacol; 2015 Sep; 28(1):313-21. PubMed ID: 26122536
[TBL] [Abstract] [Full Text] [Related]
9. Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.
Berrocal A; Arance A; Lopez Martin JA; Soriano V; Muñoz E; Alonso L; Espinosa E; Lopez Criado P; Valdivia J; Martin Algarra S;
Melanoma Res; 2014 Dec; 24(6):577-83. PubMed ID: 25046550
[TBL] [Abstract] [Full Text] [Related]
10. Expression of c-FLIP in malignant melanoma, and its relationship with the clinicopathological features of the disease.
Tian F; Lu JJ; Wang L; Li L; Yang J; Li Y; Liu YQ; Shen GX; Tu YT; Tao J
Clin Exp Dermatol; 2012 Apr; 37(3):259-65. PubMed ID: 22103668
[TBL] [Abstract] [Full Text] [Related]
11. Overall survival and PD-L1 expression in metastasized malignant melanoma.
Gadiot J; Hooijkaas AI; Kaiser AD; van Tinteren H; van Boven H; Blank C
Cancer; 2011 May; 117(10):2192-201. PubMed ID: 21523733
[TBL] [Abstract] [Full Text] [Related]
12. Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-β and valproic acid.
Roos WP; Jöst E; Belohlavek C; Nagel G; Fritz G; Kaina B
Cancer Res; 2011 Jun; 71(12):4150-60. PubMed ID: 21493591
[TBL] [Abstract] [Full Text] [Related]
13. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis.
Hemon P; Jean-Louis F; Ramgolam K; Brignone C; Viguier M; Bachelez H; Triebel F; Charron D; Aoudjit F; Al-Daccak R; Michel L
J Immunol; 2011 May; 186(9):5173-83. PubMed ID: 21441454
[TBL] [Abstract] [Full Text] [Related]
14. [Genetic markers of melanoma].
Tronov VA; Artamonov DN; Gorbacheva LB
Genetika; 2010 Feb; 46(2):168-79. PubMed ID: 20297650
[TBL] [Abstract] [Full Text] [Related]
15. Importance of fas-1377, fas-670, and fasL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case-control analysis.
Zhang H; Sun XF; Synnerstad I; Rosdahl I
Cancer J; 2007; 13(4):233-7. PubMed ID: 17762757
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma.
Wang Y; Dai DL; Martinka M; Li G
Clin Cancer Res; 2007 Jul; 13(14):4111-6. PubMed ID: 17634537
[TBL] [Abstract] [Full Text] [Related]
17. HLA-DR signaling inhibits fas-mediated apoptosis in A375 melanoma cells.
Aoudjit F; Guo W; Gagnon-Houde JV; Castaigne JG; Alcaide-Loridan C; Charron D; Al-Daccak R
Exp Cell Res; 2004 Sep; 299(1):79-90. PubMed ID: 15302575
[TBL] [Abstract] [Full Text] [Related]
18. Fatty acid synthase expression in melanoma.
Innocenzi D; Alò PL; Balzani A; Sebastiani V; Silipo V; La Torre G; Ricciardi G; Bosman C; Calvieri S
J Cutan Pathol; 2003 Jan; 30(1):23-8. PubMed ID: 12534800
[TBL] [Abstract] [Full Text] [Related]
19. Vitamin D and systemic cancer: is this relevant to malignant melanoma?
Osborne JE; Hutchinson PE
Br J Dermatol; 2002 Aug; 147(2):197-213. PubMed ID: 12174089
[TBL] [Abstract] [Full Text] [Related]
20. fas and fas ligand: expression and soluble circulating levels in cutaneous malignant melanoma.
Redondo P; Solano T; VAzquez B; Bauza A; Idoate M
Br J Dermatol; 2002 Jul; 147(1):80-6. PubMed ID: 12100188
[TBL] [Abstract] [Full Text] [Related]
[Next]
